• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    20 Stocks Moving in Monday's Pre-Market Session

    5/2/22 7:52:03 AM ET
    $BLCT
    $BTTX
    $CIG
    $DUO
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLCT alert in real time by email

    Gainers

    • SoundHound AI, Inc. (NASDAQ:SOUN) rose 64.3% to $10.68 in pre-market trading after tumbling 13% on Friday. SoundHound had their IPO on Thursday.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) shares rose 53.5% to $1.40 in pre-market trading following a 5% drop on Friday.
    • Luokung Technology Corp. (NASDAQ:LKCO) rose 23% to $0.6026 in pre-market trading.
    • BlueCity Holdings Limited (NASDAQ:BLCT) rose 14.2% to $1.44 in pre-market trading as the company entered into definitive agreement for going-private transaction.
    • Missfresh Limited (NASDAQ:MF) rose 10.1% to $0.5680 in pre-market trading after tumbling around 28% on Friday.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) rose 9.3% to $0.3060 in pre-market trading after jumping 13% on Friday.
    • Eargo, Inc. (NASDAQ:EAR) rose 8.7% to $4.11 in pre-market trading after the company issued a business update and provided guidance on its operating cash runway.
    • Fast Radius, Inc. (NASDAQ:FSRD) rose 7.5% to $0.9149 in pre-market trading after declining around 6% on Friday.
    • Evoke Pharma, Inc. (NASDAQ:EVOK) rose 7.1% to $0.5035 in pre-market trading after declining over 5% on Friday.
    • Fathom Digital Manufacturing Corporation (NYSE:FATH) rose 6.4% to $7.23 in pre-market trading.
    • Greenlight Capital Re, Ltd. (NASDAQ:GLRE) shares rose 6.4% to $7.32 in pre-market trading.
    • Moleculin Biotech, Inc. (NASDAQ:MBRX) rose 6.3% to $1.69 in pre-market trading. Moleculin Biotech recently said that the U.S. Food and Drug Administration accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent Malignant Glioma

    Don’t forget to check out our premarket coverage here .

    Losers

    • First Wave BioPharma, Inc. (NASDAQ:FWBI) shares fell 37.9% to $0.3851 in pre-market trading. First Wave BioPharma’s Chair and CEO sent letter to shareholders.
    • Vaxxinity, Inc. (NASDAQ:VAXX) shares fell 15.5% to $5.86 in pre-market trading. Vaxxinity shares jumped 84% on Friday after the company's Executive Chairman disclosed the purchase of 22,912 shares at $3.48/share.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) fell 15.3% to $1.60 in pre-market trading. Zosano implemented an additional workforce reduction impacting approximately 40% of its remaining employees and suspended GMP manufacturing operations at its Fremont, California facility.
    • Belite Bio, Inc (NASDAQ:BLTE) fell 13.5% to $9.16 in pre-market trading after jumping over 76% on Friday. Belite Bio priced its 6 million ADS IPO at $6 per ADS.
    • Companhia Energética de Minas Gerais (NYSE:CIG) fell 13.2% to $2.63 in pre-market trading.
    • Energy Focus, Inc. (NASDAQ:EFOI) shares fell 11.5% to $0.9900 in pre-market trading.
    • Aclarion, Inc. (NASDAQ:ACON) fell 6.3% to $1.94 in pre-market trading. The company recently priced its IPO at $4.35 per share.
    • IMAC Holdings, Inc. (NASDAQ:IMAC) fell 6% to $0.78 in pre-market trading.
    Get the next $BLCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCT
    $BTTX
    $CIG
    $DUO

    CompanyDatePrice TargetRatingAnalyst
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Comp En De Mn Cemig
    $CIG
    4/1/2025Neutral → Underperform
    BofA Securities
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    Comp En De Mn Cemig
    $CIG
    1/10/2025Buy → Hold
    HSBC Securities
    Comp En De Mn Cemig
    $CIG
    10/31/2024Sector Perform
    Scotiabank
    Comp En De Mn Cemig
    $CIG
    11/24/2023Buy → Neutral
    BofA Securities
    Comp En De Mn Cemig
    $CIG
    11/1/2023$2.90Hold → Buy
    HSBC Securities
    Comp En De Mn Cemig
    $CIG
    9/20/2023Neutral → Buy
    BofA Securities
    More analyst ratings

    $BLCT
    $BTTX
    $CIG
    $DUO
    SEC Filings

    View All

    Greenlight Capital Re Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GREENLIGHT CAPITAL RE, LTD. (0001385613) (Filer)

    2/5/26 4:15:20 PM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

    2/5/26 11:55:04 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Comp En De Mn Cemig

    6-K - ENERGY CO OF MINAS GERAIS (0001157557) (Filer)

    1/20/26 4:56:42 PM ET
    $CIG
    Electric Utilities: Central
    Utilities

    $BLCT
    $BTTX
    $CIG
    $DUO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCT
    $BTTX
    $CIG
    $DUO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    – Live video webcast on Wednesday, February 11th at 1:20 PM EST   HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:20 PM ESTPresenter: Walter Klemp, Founder, President, CEO and Chairman of MoleculinRegistration Link: Here About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-e

    2/5/26 9:15:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

    – Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin, bringing the total number of Annamycin treated subjects reviewed by its independent expert to 90. Data from the most recently completed clinical trials' subjects were made available to an expert in chemotherapy who is affiliated wit

    1/13/26 8:55:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

    – First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a business outlook and outlined expected upcoming milestones for its next generation non-cardiotoxic anthracycline Annamycin (also known by its generic name "naxtarubicin") and its STAT3 inhibitor WP1066. Annamycin "Annamycin is set for a number of milestones in 2026 including two

    1/12/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCT
    $BTTX
    $CIG
    $DUO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Chiao Chieh bought $600,001 worth of shares (262,009 units at $2.29), increasing direct ownership by 23% to 1,421,219 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    12/31/25 9:21:21 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Director Foley Ursuline F bought $64,591 worth of ORDINARY SHARES (5,000 units at $12.92), increasing direct ownership by 10% to 54,100 units (SEC Form 4)

    4 - GREENLIGHT CAPITAL RE, LTD. (0001385613) (Issuer)

    11/21/25 11:30:05 AM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    Director Platt Joseph P Jr bought $64,863 worth of ORDINARY SHARES (5,000 units at $12.97) (SEC Form 4)

    4 - GREENLIGHT CAPITAL RE, LTD. (0001385613) (Issuer)

    11/19/25 3:08:45 PM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    $BLCT
    $BTTX
    $CIG
    $DUO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Chiao Chieh bought $600,001 worth of shares (262,009 units at $2.29), increasing direct ownership by 23% to 1,421,219 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    12/31/25 9:21:21 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Large owner Nantahala Capital Management, Llc disposed of $1,629,683 worth of shares (148,153 units at $11.00) (SEC Form 4)

    4 - Evoke Pharma Inc (0001403708) (Issuer)

    12/19/25 4:15:35 PM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pyszczymuka Greg

    4 - Evoke Pharma Inc (0001403708) (Issuer)

    12/17/25 4:00:18 PM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCT
    $BTTX
    $CIG
    $DUO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

    H.C. Wainwright resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $4.00

    6/9/25 7:52:11 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cemig downgraded by BofA Securities

    BofA Securities downgraded Cemig from Neutral to Underperform

    4/1/25 9:01:14 AM ET
    $CIG
    Electric Utilities: Central
    Utilities

    Moleculin Biotech downgraded by Maxim Group

    Maxim Group downgraded Moleculin Biotech from Buy to Hold

    2/12/25 8:44:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCT
    $BTTX
    $CIG
    $DUO
    Financials

    Live finance-specific insights

    View All

    Greenlight Re Announces Financial Results for Third Quarter and Nine Months Ended September 30, 2025

    Achieves Record Quarterly Underwriting Income, Leading to a Combined Ratio of 86.6% GRAND CAYMAN, Cayman Islands, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Greenlight Capital Re, Ltd. (NASDAQ:GLRE) ("Greenlight Re" or the "Company") today reported its financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 Highlights (all comparisons are to third quarter 2024 unless noted otherwise): Gross premiums written increased 9.5% to $184.4 million;Net premiums earned increased 8.9% to $165.4 million;Net underwriting income of $22.3 million, compared to $6.1 million;Combined ratio of 86.6%, compared to 95.9%;Total investment loss of $17.4 million, compared to

    11/3/25 4:15:00 PM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    Greenlight Capital Re, Ltd. Schedules Third Quarter 2025 Financial Results and Conference Call

    GRAND CAYMAN, Cayman Islands, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Greenlight Capital Re, Ltd. (NASDAQ:GLRE) (the "Company" or "Greenlight Re"), a multiline property and casualty insurer and reinsurer, today announced that it expects to release financial results for the third quarter and nine-months ended September 30, 2025, after the market closes on Monday, November 3, 2025.  A live conference call to discuss the financial results will be held on Tuesday, November 4, 2025, at 9:00 a.m. Eastern Time. Conference Call Details To participate in the Greenlight Re Third Quarter 2025 Earnings Call, please dial in to the conference call at: U.S. toll free: 1-877-407-9753 International: 1-201-493

    10/28/25 4:15:00 PM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    Greenlight Re Announces Financial Results for Second Quarter and Six Months Ended June 30, 2025

    Delivers 95.0% Combined Ratio and Returns $5 million to Shareholders Through Buybacks GRAND CAYMAN, Cayman Islands, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Greenlight Capital Re, Ltd. (NASDAQ:GLRE) ("Greenlight Re" or the "Company") today reported its financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 Highlights (all comparisons are to second quarter 2024 unless noted otherwise): Gross premiums written increased 6.3% to $179.6 million;Net premiums earned increased 2.0% to $161.6 million;Net underwriting income of $8.1 million, compared to $0.3 million;Combined ratio of 95.0%, compared to 99.9%;Total investment loss of $7.8 million, compared

    8/4/25 4:15:00 PM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    $BLCT
    $BTTX
    $CIG
    $DUO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCT
    $BTTX
    $CIG
    $DUO
    Leadership Updates

    Live Leadership Updates

    View All

    Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

    40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of global healthcare markets. He has held senior executive roles across diverse regions, including overseeing U.S. supply c

    7/17/25 8:25:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenlight Re Announces Appointment of Martin Vezina as Head of Underwriting Analytics

    GRAND CAYMAN, Cayman Islands, May 01, 2025 (GLOBE NEWSWIRE) -- Greenlight Reinsurance, Ltd. ("Greenlight Re" or the "Company"), a subsidiary of Greenlight Capital Re, Ltd. (NASDAQ:GLRE), today announced the appointment of Martin Vezina as Head of Underwriting Analytics with immediate effect. In this capacity, Vezina will play a pivotal role in overseeing Greenlight Re's underwriting analytics and pricing function and will be based out of the Company's headquarters in Grand Cayman. "I am excited to join Greenlight Re and look forward to the continued enhancement of the Company's underwriting platform. Through my prior collaboration with various members of the Greenlight Re team, I have com

    5/1/25 9:00:00 AM ET
    $GLRE
    Property-Casualty Insurers
    Finance

    Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

    SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commer

    2/24/25 8:30:37 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care